ICAP PrEP Package for Providers: PrEParing for Choice

9 February 2024

ICAP’s PrEP Package for Providers: PrEParing for Choice was developed by ICAP at Columbia University to promote the introduction and implementation of multiple PrEP products. The material is designed to capacitate health care teams with the knowledge and skills to counsel clients about PrEP and PrEP options, conduct effective PrEP initiation visits, and monitor and support ongoing PrEP use.

Support for PrEP Choice: The toolkit reflects current World Health Organization recommendations on oral daily PrEP; event-driven PrEP; long-acting injectable cabotegravir as PrEP; the dapivirine vaginal ring; and person-centered PrEP counseling.

PrEP products are presented in stand-alone modules that can be combined according to PrEP product availability and program training needs. The counseling module includes training on informed choice counseling to help clients decide which available PrEP option is best for them.

Featured Resources

External Link

A Mixed-Method Study of Feasibility and Acceptability of the Dapivirine Vaginal Ring among Adolescent Girls and Young Women (AGYW) in Selected Zimbabwean Districts

This article from PLOS Global Public Health describes the results of a study assessing the acceptability and feasibility of introducing the dapivirine vaginal ring (DVR) as an HIV prevention method among young women in Zimbabwe and to assess motivations and barriers of DVR uptake among the target population.

Spreadsheet

2024 Q4 Global PrEP Tracker

AVAC’s Global PrEP Tracker offers two views on PrEP uptake around the world. Visit data.prepwatch.org for a dynamic map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs. For insights on the full scope of PrEP use around the world, the PrEP Tracker as a spreadsheet offers…

External Link

HIVR4P 2024 Knowledge Toolkit

The HIVR4P 2024 Knowledge Toolkit highlights important scientific advancements and innovative research across key thematic areas presented at the HIVR4P 2024 conference. Thematic areas include the PURPOSE 2 trial of long-acting lenacapavir for PrEP, data on the three-month dapivirine vaginal ring, and early evidence on offering a choice of PrEP methods.

External Link

Safety and Drug Quantification of the Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis in Breastfeeding Mother–Infant Pairs (MTN-043): A phase 3B, open-label, randomised trial

This article from The Lancet HIV discusses the results of the Microbicide Trials Network (MTN)-043 trial, which assessed the safety of use of the dapivirine vaginal ring during breastfeeding amongst participants in Malawi, South Africa, Uganda, and Zimbabwe.

MTN-020 ASPIRE

Archived from the MTN website before it was taken down. Archived MTN ASPIRE news page available here. Primary Objectives Determine the effectiveness of dapivirine (25 mg) administered in a silicone elastomer matrix vaginal ring (VR), when inserted once every 4 weeks, in preventing HIV-1 infection among healthy sexually active HIV-uninfected women Assess the safety of…

External Link

Interest in Injectable and Oral PrEP for HIV Prevention Among Women and Men Who Inject Drugs

This article from Journal of Addiction Medicine examines interests and concerns around use of oral and injectable PrEP amongst people who inject drugs in the United States.

Document

PrEP Booklet of Frequently Asked Questions (FAQs): A Peer Outreach Worker Tool

This tool was developed to be used by peer outreach workers, peer educators, and other community-based health providers to help provide comprehensive information about pre-exposure prophylaxis (PrEP) to key population peers.

External Link

Determinants of Continuation on HIV Pre-exposure Propylaxis among Female Sex Workers at a Referral Hospital in Uganda: A mixed methods study using COM-B model

This article from BMC Public Health describes the results of a study to evaluate PrEP continuation among female sex workers and explore potential determinants of PrEP adherence within a public referral hospital in urban Uganda.

Document

Oral PrEP Factsheet

This adaptable factsheet can be used by program implementers to raise awareness about oral pre-exposure prophylaxis (PrEP). It highlights tips for using oral PrEP, side effects, and dosing regimens for different groups of people.

Document

Long-Acting PrEP for Key Populations: Considerations for Implementation

This document is intended for program implementers, advocates, policymakers, and other stakeholders who influence the rollout of long-acting options for pre-exposure prophylaxis (PrEP). It highlights some of the considerations for long-acting PrEP implementation for key population individuals.